HGFR/c-MET Antibody (95106) [Unconjugated]

MDA‑MB‑231 human breast cancer cell line was stained with Human HGF R/c‑MET Monoclonal Antibody (Catalog # MAB3582, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG F(ab')2 Secondary Antibody (Catalog # F0101B).

• Reactivity: Hu
• Applications: Flow, CyTOF-ready
• Clone: 95106
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

HGFR/c-MET Antibody (95106) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human HGF R/c-MET
  Glu25-Thr932
  Accession # P08581
• Specificity: Detects human HGF R/c-MET.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: MET
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 2.5 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for HGFR/c-MET Antibody (95106) [Unconjugated]

• AUTS9
• cMET
• c-MET
• EC 2.7.10
• EC 2.7.10.1
• hepatocyte growth factor receptor
• HGF R
• HGF receptor
• HGF/SF receptor
• HGFR
• Met (c-Met)
• met proto-oncogene (hepatocyte growth factor receptor)
• met proto-oncogene tyrosine kinase
• MET
• oncogene MET
• Proto-oncogene c-Met
• RCCP2
• Scatter factor receptor
• SF receptor
• Tyrosine-protein kinase Met

Background

HGF R, also known as Met (from N-methyl-N’-nitro-N-nitrosoguanidine induced), is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGF R is synthesized as a single chain precursor which undergoes cotranslational proteolytic cleavage. This generates a mature HGF R that is a disulfide-linked dimer composed of a 50 kDa extracellular alpha chain and a 145 kDa transmembrane beta chain (1, 2). The extracellular domain (ECD) contains a seven bladed beta -propeller sema domain, a cysteine-rich PSI/MRS, and four Ig-like E-set domains, while the cytoplasmic region includes the tyrosine kinase domain (3, 4). Proteolysis and alternate splicing generate additional forms of human HGF R which either lack of the kinase domain, consist of secreted extracellular domains, or are deficient in proteolytic separation of the alpha and beta chains (5-7). The sema domain, which is formed by both the alpha and beta chains of HGF R, mediates both ligand binding and receptor dimerization (3, 8). Ligand-induced tyrosine phosphorylation in the cytoplasmic region activates the kinase domain and provides docking sites for multiple SH2-containing molecules (9, 10). HGF stimulation induces HGF R downregulation via internalization and proteasome-dependent degradation (11). In the absence of ligand, HGF R forms non-covalent complexes with a variety of membrane proteins including CD44v6, CD151, EGF R, Fas, Integrin alpha 6/ beta 4, Plexins B1, 2, 3, and MSP R/Ron (12-19). Ligation of one complex component triggers activation of the other, followed by cooperative signaling effects (12-19). Formation of some of these heteromeric complexes is a requirement for epithelial cell morphogenesis and tumor cell invasion (12, 16, 17). Paracrine induction of epithelial cell scattering and branching tubulogenesis results from the stimulation of HGF R on undifferentiated epithelium by HGF released from neighboring mesenchymal cells (20). Genetic polymorphisms, chromosomal translocation, over-expression, and additional splicing and proteolytic cleavage of HGF R have been described in a wide range of cancers (1). Within the ECD, human HGF R shares 86-88% amino acid sequence identity with canine, mouse, and rat HGF R.

1. Birchmeier, C. et al. (2003) Nat. Rev. Mol. Cell Biol. 4:915.
2. Corso, S. et al. (2005) Trends Mol. Med. 11:284.
3. Gherardi, E. et al. (2003) Proc. Natl. Acad. Sci. USA 100:12039.
4. Park, M. et al. (1987) Proc. Natl. Acad. Sci. USA 84:6379.
5. Crepaldi, T. et al. (1994) J. Biol. Chem. 269:1750.
6. Prat, M. et al. (1991) Mol. Cell. Biol. 12:5954.
7. Rodrigues, G.A. et al. (1991) Mol. Cell. Biol. 11:2962.
8. Kong-Beltran, M. et al. (2004) Cancer Cell 6:75.
9. Naldini, L. et al. (1991) Mol. Cell. Biol. 11:1793.
10. Ponzetto, C. et al. (1994) Cell 77:261.
11. Jeffers, M. et al. (1997) Mol. Cell. Biol. 17:799.
12. Orian-Rousseau, V. et al. (2002) Genes Dev. 16:3074.
13. Klosek, S.K. et al. (2005) Biochem. Biophys. Res. Commun. 336:408.
14. Jo, M. et al. (2000) J. Biol. Chem. 275:8806.
15. Wang, X. et al. (2002) Mol. Cell 9:411.
16. Trusolino, L. et al. (2001) Cell 107:643.
17. Giordano, S. et al. (2002) Nat. Cell Biol. 4:720.
18. Conrotto, P. et al. (2004) Oncogene 23:5131.
19. Follenzi, A. et al. (2000) Oncogene 19:3041.
20. Sonnenberg, E. et al. (1993) J. Cell Biol. 123:223.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for HGFR/c-MET Antibody (MAB3582)(14)

Publications using MAB3582

• CH Kang, Y Kim, DY Lee, SU Choi, HK Lee, CH Park c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer Cancers, 2021-11-16;13(22):. 2021-11-16 [PMID: 34830894] (Flow Cytometry, Human)
• KD Wurster, M Costanza, S Kreher, S Glaser, B Lamprecht, N Schleussne, I Anagnostop, M Hummel, K Jöhrens, H Stein, A Molina, A Diepstra, B Gillissen, K Köchert, R Siebert, O Merkel, L Kenner, M Janz, S Mathas Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL) Cancers, 2021-10-07;13(19):. 2021-10-07 [PMID: 34638496] (Flow Cytometry, Human)
• S Di Franco, P Bianca, DS Sardina, A Turdo, M Gaggianesi, V Veschi, A Nicotra, LR Mangiapane, M Lo Iacono, I Pillitteri, S van Hooff, F Martorana, G Motta, E Gulotta, VL Lentini, E Martorana, ME Fiori, S Vieni, MR Bongiorno, G Giannone, D Giuffrida, L Memeo, L Colarossi, M Mare, P Vigneri, M Todaro, R De Maria, JP Medema, G Stassi Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery Nature Communications, 2021-08-18;12(1):5006. 2021-08-18 [PMID: 34408135] (ICC, Human)
• F De Bacco, F Orzan, J Erriquez, E Casanova, L Barault, R Albano, A D'Ambrosio, V Bigatto, G Reato, M Patanè, B Pollo, G Kuesters, C Dell'Aglio, L Casorzo, S Pellegatta, G Finocchiar, PM Comoglio, C Boccaccio ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma Cell Reports, 2021-07-27;36(4):109455. 2021-07-27 [PMID: 34320350] (Flow Cytometry, Human)
• T Khan, AM Seddon, AG Dalgleish, S Khelwatty, N Ioannou, S Mudan, H Modjtahedi Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer Oncol Rep, 2020-10-22;0(0):. 2020-10-22 [PMID: 33125153] (Flow Cytometry, Human)
• BW Stringer, BW Day, RCJ D'Souza, PR Jamieson, KS Ensbey, ZC Bruce, YC Lim, K Goasdoué, C Offenhäuse, S Akgül, S Allan, T Robertson, P Lucas, G Tollesson, S Campbell, C Winter, H Do, A Dobrovic, PL Inglis, RL Jeffree, TG Johns, AW Boyd A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma Sci Rep, 2019-03-20;9(1):4902. 2019-03-20 [PMID: 30894629] (Flow Cytometry, Human)
• Christian Breunig, Nese Erdem, Alexander Bott, Julia F. Greiwe, Eileen Reinz, Stephan Bernhardt et al. TGF beta 1 regulates HGF ‐induced cell migration and hepatocyte growth factor receptor MET expression via C‐ets‐1 and miR‐128‐3p in basal‐like breast cancer Molecular Oncology 2018-09-01 [PMID: 30004628]
• W Zhang, R Duan, J Zhang, WKC Cheung, X Gao, R Zhang, Q Zhang, M Wei, G Wang, Q Zhang, PJ Mei, HL Chen, H Kung, MC Lin, Z Shen, J Zheng, L Zhang, H Yao H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma Br. J. Cancer, 2018-01-18;0(0):. 1/18/2018 [PMID: 29348487]
• R Montagne, M Berbon, L Doublet, N Debreuck, A Baranzelli, H Drobecq et al. Necrosis- and apoptosis-related Met cleavages have divergent functional consequences Cell Death & Disease 2015-05-21 [PMID: 25996296]
• Vogel S, Borger V, Peters C, Forster M, Liebfried P, Metzger K, Meisel R, Daubener W, Trapp T, Fischer J, Gawaz M, Sorg R Necrotic cell-derived high mobility group box 1 attracts antigen-presenting cells but inhibits hepatocyte growth factor-mediated tropism of mesenchymal stem cells for apoptotic cell death. Cell Death Differ, 2015-01-09;22(7):1219-30. 2015-01-09 [PMID: 25571972] (Flow Cytometry, Human)
• Carbonell W, DeLay M, Jahangiri A, Park C, Aghi M beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res, 2013-05-03;73(10):3145-54. 2013-05-03 [PMID: 23644530] (Flow Cytometry, Human)
• Ling Xu, Martin Hausmann, Wolfgang Dietmaier, Silvia Kellermeier, Theresa Pesch, Manuela Stieber-Gunckel et al. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines BMC Cancer 2010-12-01 [PMID: 20565817]
• Foveau B, Ancot F, Leroy C, Petrelli A, Reiss K, Vingtdeux V, Giordano S, Fafeur V, Tulasne D Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol. Biol. Cell, 2009-03-18;20(9):2495-507. 2009-03-18 [PMID: 19297528] (Flow Cytometry, Human)
• Riccioni R, Senese M, Diverio D, Riti V, Mariani G, Boe A, LoCoco F, Foa R, Peschle C, Sporn M, Testa U Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels. Leuk. Res., 2008-03-04;32(8):1244-58. 2008-03-04 [PMID: 18304628] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: MET
• Uniprot:
  • P08581()